Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration

• Published in: Journal of antimicrobial chemotherapy 2016-02, Vol.71 (2), p.464-470
• Main Authors: Roger, C, Muller, L, Wallis, S C, Louart, B, Saissi, G, Lipman, J, Lefrant, J Y, Roberts, J A
• Format: Article
• Language: English
• Subjects: Aged; Anti-Bacterial Agents - pharmacokinetics; Blood Chemical Analysis; Chromatography; Comparative analysis; Critical Illness; Female; Hemodiafiltration; Hemofiltration; Hormone replacement therapy; Human health and pathology; Humans; Infectious diseases; Life Sciences; Linezolid - pharmacokinetics; Male; Microbial Sensitivity Tests; Microbiology and Parasitology; Middle Aged; Parameter estimation; Pharmaceutical sciences; Pharmacology; Prospective Studies
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dkv349

Few data are available to guide linezolid dosing during renal replacement therapy. The objective of this study was to compare the population pharmacokinetics of linezolid during continuous venovenous haemofiltration (CVVHF, 30 mL/kg/h) and continuous venovenous haemodiafiltration (CVVHDF, 15 mL/kg/h + 15 mL/kg/h). Patients requiring linezolid 600 mg iv every 12 h and CVVHF or CVVHDF were eligible for this prospective study. Seven blood samples were collected over one dosing interval and analysed by a validated chromatographic method. Population pharmacokinetic analysis was undertaken using Pmetrics. Monte Carlo simulations evaluated achievement of a pharmacodynamics target of an AUC from 0-24 h to MIC (AUC0-24/MIC) of 80. Nine CVVHDF and eight CVVHF treatments were performed in 13 patients. Regimens of CVVHDF and CVVHF were similar. A two-compartment linear model best described the data. CVVHDF was associated with a 20.5% higher mean linezolid clearance than CVVHF, without statistical significance (P = 0.39). Increasing patient weight and decreasing SOFA score were associated with increasing linezolid clearance. The mean (SD) parameter estimates were: clearance (CL), 3.8 (2.2) L/h; volume of the central compartment, 26.5 (10.3) L; intercompartmental clearance constants from central to peripheral, 8.1 (12.1) L/h; and peripheral to central compartments, 3.6 (4.0) L/h. Achievement of pharmacodynamic targets was poor for an MIC of 2 mg/L with the studied dose. During CVVHF and CVVHDF, there is profound pharmacokinetic variability of linezolid. Suboptimal achievement of therapeutic targets occurs at the EUCAST breakpoint MIC of 2 mg/L using 600 mg iv every 12 h.